What Is the Optimal Duration of Antiplatelet Therapy for Patients with Coronary Heart Disease?

被引：0
|
作者：
Beryl Otieno
Chukwuka Ibecheozor
Marlene S. Williams
机构：
[1] Greater Baltimore Medical Center,Division of Cardiology
[2] The Johns Hopkins University School of Medicine,undefined
[3] The Johns Hopkins University School of Medicine,undefined
来源：
Current Atherosclerosis Reports | 2023年 / 25卷
关键词：
Antiplatelet therapy; Ischemia; Dual antiplatelet therapy; Bleeding; Coronary heart disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：343 / 350
页数：7
相关论文
共 50 条
  • [21] THE OPTIMAL DURATION OF DUAL ANTIPLATELET THERAPY IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS
    Ma Yi-Tong
    Yu Zi-Xiang
    Yang Yi-Ning
    Bayinsilema, Ba
    HEART, 2013, 99 : A48 - A48
  • [22] Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents
    Marco Zimarino
    Giulia Renda
    Raffaele De Caterina
    Drugs, 2005, 65 : 725 - 732
  • [23] Progress Analysis of Personalized Antiplatelet Therapy in Patients with Coronary Heart Disease Undergoing Interventional Therapy
    Yang, Ji-tong
    Zhang, Qiu-juan
    Li, Hua
    Liu, Ming-wei
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2024, 25 (12)
  • [24] Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease
    Bittl, John A.
    Baber, Usman
    Bradley, Steven M.
    Wijeysundera, Duminda N.
    Halperin, Jonathan L.
    Levine, Glenn N.
    Al-Khatib, Sana M.
    Birtcher, Kim K.
    Bozkurt, Biykem
    Brindis, Ralph G.
    Cigarroa, Joaquin E.
    Curtis, Lesley H.
    Fleisher, Lee A.
    Gentile, Federico
    Gidding, Samuel
    Hlatky, Mark A.
    Ikonomidis, John S.
    Joglar, Jose A.
    Pressler, Susan J.
    Wijeysundera, Duminda N.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (10) : 1116 - 1139
  • [25] Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome
    Deharo, Pierre
    Cuisset, Thomas
    TRENDS IN CARDIOVASCULAR MEDICINE, 2020, 30 (04) : 198 - 202
  • [26] Duration of Dual Antiplatelet Therapy in Coronary Artery Disease: a Review Article
    Alex D. Moseley
    Fareed M. Collado
    Annabelle Santos Volgman
    Gary L. Schaer
    R. Jeffrey Snell
    Current Atherosclerosis Reports, 2016, 18
  • [27] Duration of Dual Antiplatelet Therapy in Coronary Artery Disease: a Review Article
    Moseley, Alex D.
    Collado, Fareed M.
    Volgman, Annabelle Santos
    Schaer, Gary L.
    Snell, R. Jeffrey
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (07)
  • [28] Antiplatelet drug resistance in patients with coronary heart disease
    Sulimov, V. A.
    Moroz, E., V
    CARDIOVASCULAR THERAPY AND PREVENTION, 2012, 11 (06): : 71 - 77
  • [29] DURATION OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE AFTER IMPLANTATION OF ENDOVASCULAR STENTS
    Sumarokov, A. B.
    Buryachkovskaya, L., I
    Lomakin, N., V
    Dotsenko, Yu, V
    Uchitel, I. A.
    Timofeeva, L. A.
    KARDIOLOGIYA, 2018, 58 (01) : 41 - 52
  • [30] The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism
    Bockeria, O. L.
    Kudzoeva, Z. F.
    Shvarts, V. A.
    Koasari, A. K.
    Donakanyan, S. A.
    TERAPEVTICHESKII ARKHIV, 2016, 88 (05) : 47 - 54
12345